Latest Global Rollout News

RocketBoots has begun installing its global retail contract in US stores and received its first payment, but quarterly operating cash outflows of A$1.75 million left the company with an estimated 1.03 quarters of funding. Management is relying on incoming customer receipts, an R&D tax refund and a new A$5 million invoice financing facility to support the rollout.

Saluda Medical delivered 28% FY26 revenue growth and expanded its spinal cord stimulation opportunity with CAP24, but its annual report warns that additional capital may be needed within 12 months. The ASX-listed medical device company also begins FY27 under new CEO Michael Mathias.

Lovisa delivered another year of strong reported growth, with revenue rising 17.6% to A$938.8 million as its store network passed 1,100 locations. But comparable store sales grew just 2.0%, leaving management’s expansion engine carrying more of the load while executive incentive hurdles went unmet.

RocketBoots has moved its major multinational retailer contract from integration into live US store installations, issuing its first €84,445 invoice for cloud activation and initial deployments. The milestone puts the company closer to accessing approximately A$9.1 million in annual recurring revenue, although the wider rollout remains phased and customer-led.

Clever Culture Systems secures a follow-up order from Novo Nordisk for two APAS Independence instruments, marking a critical step toward broader global deployment and signalling expected sales growth from FY27.

RocketBoots reported a 9.7% revenue rise to A$724,815 but deepened its net loss to A$6.6 million, driven by heavy investment ahead of a major contract rollout and international growth.

Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

Memphasys has locked in a 12-month exclusive supply agreement with Monash IVF for its Felix™ sperm selection system, marking its biggest commercial contract to date and setting a foundation for recurring revenue.

TZ Limited (ASX:TZL) is raising $3.08 million through a $0.50 million placement and a $2.58 million entitlement offer at 3 cents per share to repay debt, fund acquisitions, and accelerate product development.

IPH Limited has appointed Tony O’Malley as its new CEO starting July 2026, bringing over 30 years of global legal and professional services experience, including AI-driven transformation expertise.

RocketBoots has secured a significant A$3.3 million activation contract with a tier-one multinational retailer and reported over 50% growth in its early sales pipeline, supported by a strong cash position of A$5 million.